A Safety and Efficacy Study of Sufentanil Transdermal System in Patients With Chronic Pain Due to Cancer
Primary Purpose
Chronic Pain
Status
Withdrawn
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Sufentanil
Sustained Release Morphine Sulfate
Sponsored by
About this trial
This is an interventional treatment trial for Chronic Pain focused on measuring Pain, Cancer, Morphine
Eligibility Criteria
Inclusion Criteria:
- Male or female patients aged 18 to 75 with a diagnosis of cancer;
- If female, is non-pregnant (negative pregnancy test at Visit 1) and non-lactating;
- If female, is not of childbearing potential
- Documented history of moderate to severe chronic cancer pain requiring around-the-clock therapy and are likely to benefit from WHO step III opioid analgesics for the duration of the study;
- Has been informed of the nature of the study and has provided written informed consent;
- Is willing, able, and competent to complete the entire study and comply with study instructions
Exclusion Criteria:
- Patient is a pregnant or lactating female (serum pregnancy test conducted at the Screening Visit);
- Any ongoing serious adverse events (SAEs) at screening and at baseline;
- Has scheduled elective surgery or other invasive procedures during the period of study participation;
- Patients with a known intolerance to opioid analgesics or any excipient of the Investigational Product;
- Patients with respiratory depression with hypoxia and/or hypercapnia, sever chronic obstructive pulmonary disease, cor pulmonale, severe bronchial asthma, paralytic ileus, (obstructive) sleep apnea syndrome;
- Evidence of clinically significant cardiovascular, renal, hepatic or psychiatric disease, as determined by medical history, clinical laboratory tests, ECG results, and physical examination, that would place the patient at risk upon exposure to the study medication or that may confound the analysis and/or interpretation of the results;
- Abnormal aspartate aminotransferase (AST; SGOT), alanine aminotransferase (ALT; SGPT), or alkaline phosphatase levels (> 3 times the upper level of normal) or an abnormal total bilirubin level (> 1.5 times the upper level of normal) or creatinine clearance < 50 ml/min (calculated using the Cockcroft-Gault formula);
- Patients with uncontrolled seizures;
- Patients with increased intracranial pressure;
- Patients who are receiving hypnotics or other central nervous system (CNS) depressants that, in the opinion of the investigator, may pose a risk of additional CNS depression with opioid medication;
- Patients with myxoedema, inadequately controlled hypothyroidism or Addisons disease;
- History of alcohol and/or drug abuse (or a positive urine drug screen at Visit 1) within one year preceding the Screening Visit;
- Active skin disease;
- Patients suffering from diarrhea and/or opioid withdrawal;
- Known positive Hepatitis B or C or HIV status;
- Has participated in another clinical study of drugs or devices parallel to or < 1 month before study entry, or previous participation in this study;
- Is an employee of the investigator or study site with direct involvement in the proposed study or other studies under the direction of that investigator or study site, or is a family member of the employees or the investigator.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Sufentanil Transdermal Delivery System
Control
Arm Description
Experimental drug
Sustained release morphine sulfate
Outcomes
Primary Outcome Measures
The consumption (in mg) of rescue analgesia (normal release morphine sulfate tablets) per day after the administration of either sufentanil TDS or SR morphine sulfate.
Secondary Outcome Measures
Adverse events
Pharmacokinetic data
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00943566
Brief Title
A Safety and Efficacy Study of Sufentanil Transdermal System in Patients With Chronic Pain Due to Cancer
Official Title
A Multicenter, Open-label, Randomized, Parallel Group Study to Compare the Efficacy and Safety of Sufentanil Transdermal System (TDS) With Sustained-Release Morphine Sulfate in Patients With Chronic Pain Due to Cancer
Study Type
Interventional
2. Study Status
Record Verification Date
June 2011
Overall Recruitment Status
Withdrawn
Why Stopped
funding for project discontinued
Study Start Date
January 2010 (undefined)
Primary Completion Date
December 2010 (Anticipated)
Study Completion Date
February 2011 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
Labtec GmbH
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The study hypothesis is that the safety and efficacy of sufentanil following transdermal application is comparable to sustained release morphine sulphate tablets in patients with chronic pain due to cancer.
Detailed Description
The primary objective of this study is to compare the consumption, in milligrams, of rescue analgesia (normal release morphine sulfate tablets) after the administration of sufentanil TDS or sustained release morphine sulfate.
The secondary efficacy objectives of this study are to evaluate:
Pharmacokinetic data
Adverse events
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Pain
Keywords
Pain, Cancer, Morphine
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Sufentanil Transdermal Delivery System
Arm Type
Experimental
Arm Description
Experimental drug
Arm Title
Control
Arm Type
Active Comparator
Arm Description
Sustained release morphine sulfate
Intervention Type
Drug
Intervention Name(s)
Sufentanil
Intervention Description
Transdermal Delivery System; Apply up to six 3 cm2 sufentanil TDS patches every 3 days for 12 days of observation. The 12 days of observation begin after a 7 day conversion to sustained release morphine sulfate. If the subject continues on the pharmacokinetic portion of the study, an additional 6 days of intervention will be evaluated (at the same dose as the primary efficacy study).
Intervention Type
Drug
Intervention Name(s)
Sustained Release Morphine Sulfate
Intervention Description
Sustained Release Morphine Sulfate tablets every 12 hours; up to 400 mg every day for 19 days (7 days of conversion to sustained release morphine sulfate and 12 days of observation)
Primary Outcome Measure Information:
Title
The consumption (in mg) of rescue analgesia (normal release morphine sulfate tablets) per day after the administration of either sufentanil TDS or SR morphine sulfate.
Time Frame
6 days
Secondary Outcome Measure Information:
Title
Adverse events
Time Frame
18 days
Title
Pharmacokinetic data
Time Frame
6 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or female patients aged 18 to 75 with a diagnosis of cancer;
If female, is non-pregnant (negative pregnancy test at Visit 1) and non-lactating;
If female, is not of childbearing potential
Documented history of moderate to severe chronic cancer pain requiring around-the-clock therapy and are likely to benefit from WHO step III opioid analgesics for the duration of the study;
Has been informed of the nature of the study and has provided written informed consent;
Is willing, able, and competent to complete the entire study and comply with study instructions
Exclusion Criteria:
Patient is a pregnant or lactating female (serum pregnancy test conducted at the Screening Visit);
Any ongoing serious adverse events (SAEs) at screening and at baseline;
Has scheduled elective surgery or other invasive procedures during the period of study participation;
Patients with a known intolerance to opioid analgesics or any excipient of the Investigational Product;
Patients with respiratory depression with hypoxia and/or hypercapnia, sever chronic obstructive pulmonary disease, cor pulmonale, severe bronchial asthma, paralytic ileus, (obstructive) sleep apnea syndrome;
Evidence of clinically significant cardiovascular, renal, hepatic or psychiatric disease, as determined by medical history, clinical laboratory tests, ECG results, and physical examination, that would place the patient at risk upon exposure to the study medication or that may confound the analysis and/or interpretation of the results;
Abnormal aspartate aminotransferase (AST; SGOT), alanine aminotransferase (ALT; SGPT), or alkaline phosphatase levels (> 3 times the upper level of normal) or an abnormal total bilirubin level (> 1.5 times the upper level of normal) or creatinine clearance < 50 ml/min (calculated using the Cockcroft-Gault formula);
Patients with uncontrolled seizures;
Patients with increased intracranial pressure;
Patients who are receiving hypnotics or other central nervous system (CNS) depressants that, in the opinion of the investigator, may pose a risk of additional CNS depression with opioid medication;
Patients with myxoedema, inadequately controlled hypothyroidism or Addisons disease;
History of alcohol and/or drug abuse (or a positive urine drug screen at Visit 1) within one year preceding the Screening Visit;
Active skin disease;
Patients suffering from diarrhea and/or opioid withdrawal;
Known positive Hepatitis B or C or HIV status;
Has participated in another clinical study of drugs or devices parallel to or < 1 month before study entry, or previous participation in this study;
Is an employee of the investigator or study site with direct involvement in the proposed study or other studies under the direction of that investigator or study site, or is a family member of the employees or the investigator.
12. IPD Sharing Statement
Learn more about this trial
A Safety and Efficacy Study of Sufentanil Transdermal System in Patients With Chronic Pain Due to Cancer
We'll reach out to this number within 24 hrs